School of Pharmaceutical Science, Sun Yat-sen University, Guangzhou, People's Republic of China.
Phytother Res. 2011 Aug;25(8):1250-3. doi: 10.1002/ptr.3407. Epub 2011 Feb 1.
Wuzhi tablet (WZ, registration no. in China: Z20025766) is a preparation of an ethanol herb extract of Wuweizi (Schisandra sphenanthera) containing 7.5 mg Schisantherin A per tablet. It was reported recently that WZ could significantly increase the blood concentrations of tacrolimus, which might be due to the inhibitory effect of WZ and its ingredients on P-gp and/or CYP450 activity. Paclitaxel is a substrate of the efflux transporter P-gp, and is mainly metabolized by CYP450 enzymes in the liver. Therefore, the purpose of this study was to investigate whether and how WZ affects the pharmacokinetics of paclitaxel in rats. After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05). The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05). Thus, the presence of WZ improved the systemic exposure of paclitaxel in rats. The herb-drug interaction between WZ and paclitaxel should be taken into consideration in clinical use.
五酯片(WZ,中国注册编号:Z20025766)是一种五味子(Schisandra sphenanthera)乙醇提取物制剂,每片含五味子甲素 7.5μg。最近有报道称,WZ 可显著提高他克莫司的血药浓度,这可能是由于 WZ 及其成分对 P-糖蛋白和/或 CYP450 活性的抑制作用。紫杉醇是外排转运蛋白 P-糖蛋白的底物,主要在肝脏中通过 CYP450 酶代谢。因此,本研究旨在探讨 WZ 是否以及如何影响紫杉醇在大鼠体内的药代动力学。经 WZ 预处理后,口服紫杉醇的 AUC(0-24h)(从 280.8±97.3 到 543.5±115.2 hng/mL;p<0.05)和 Cmax(从 44.6±16.4 到 86.8±16.1 ng/mL;p<0.05)显著增加。WZ 对静脉注射紫杉醇的药代动力学数据显示,与口服紫杉醇相比,AUC(0-24h)(从 163.6±22.1 到 212.7±17.7 hng/mL;p<0.05)略有增加,但仍有显著差异,清除率降低(从 3.2±0.6 到 2.2±0.3 L/h/kg;p<0.05)。因此,WZ 可提高紫杉醇在大鼠体内的全身暴露量。在临床应用中,应考虑 WZ 与紫杉醇之间的草药-药物相互作用。